Neoadjuvant personalized cancer vaccines: the final frontier?
ABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and la...
Saved in:
Main Authors: | Guilhem Richard (Author), Nicole Ruggiero (Author), Gary D. Steinberg (Author), William D. Martin (Author), Anne S. De Groot (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the Microenvironment in MDS: The Final Frontier
by: Patric Teodorescu, et al.
Published: (2020) -
Hearing loss: The final frontier of pharmacology
by: Alan C. Foster, et al.
Published: (2022) -
HIV persistence in the CNS: the final frontier for a cure?
by: S.h.a.r.o.n.R. Lewin, et al.
Published: (2016) -
Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014) -
Palbociclib in breast cancer neoadjuvant setting
by: Sílvia Alexandra Cabral Duarte, et al.
Published: (2021)